Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer

Molecular Aspects of Medicine

Volumn 45, Issue , 2015, Pages 55-66

  Kumar, Mukesh ^a   Ernani, Vinicius ^a   Owonikoko, Taofeek K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALK; Biomarkers; EGFR; Lung cancer; NSCLC; RET; ROS1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CABOZANTINIB; CERITINIB; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; LENVATINIB; MICROTUBULE ASSOCIATED PROTEIN 4; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PONATINIB; PROTEIN KINASE B; PROTEIN RET; RAF PROTEIN; RAS PROTEIN; TUMOR MARKER; VANDETANIB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN; ROS1 PROTEIN, HUMAN;

ADVANCED CANCER; ALK GENE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EGFR GENE; EML4 GENE; ENZYME PHOSPHORYLATION; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTRACELLULAR SIGNALING; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROS1 GENE; SURVIVAL RATE; SURVIVAL TIME; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 84946489325     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2015.06.009     Document Type: Review

References (129)

1. J. Acquaviva, R. Wong, and A. Charest The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer Biochim. Biophys. Acta 1795 1 2009 37 52 10.1016/j.bbcan.2008.07.006 18778756
2. Anonymous Ceritinib gains FDA approval for lung cancer Cancer Discov 4 7 2014 753 754 10.1158/2159-8290.CD-NB2014-074 25002599
3. M.E. Arcila, J.E. Chaft, K. Nafa, S. Roy-Chowdhuri, C. Lau, M. Zaidinski, and et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas Clin. Cancer Res 18 18 2012 4910 4918 10.1158/1078-0432.CCR-12-0912 22761469 PubMed Central PMCID: PMC3865806
4. M.M. Awad, J.A. Engelman, and A.T. Shaw Acquired resistance to crizotinib from a mutation in CD74-ROS1 N. Engl. J. Med 369 12 2013 1173 10.1056/NEJMc1309091 24047072
5. M.N. Balak, Gong Y., G.J. Riely, R. Somwar, Li A.R., M.F. Zakowski, and et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin. Cancer Res 12 21 2006 6494 6501 10.1158/1078-0432.CCR-06-1570 Epub 2006/11/07 17085664
6. J. Bean, C. Brennan, J.Y. Shih, G. Riely, A. Viale, Wang L., and et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc. Natl. Acad. Sci. U.S.A. 104 52 2007 20932 20937 10.1073/pnas.0710370104 Epub 2007/12/21 18093943 PubMed Central PMCID: PMC2409244
7. E.M. Berge, and R.C. Doebele Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor Semin. Oncol 41 1 2014 110 125 10.1053/j.seminoncol.2013.12.006 24565585 PubMed Central PMCID: PMC4159759
8. K. Bergethon, A.T. Shaw, Ou S.H., R. Katayama, C.M. Lovly, N.T. McDonald, and et al. ROS1 rearrangements define a unique molecular class of lung cancers J. Clin. Oncol 30 8 2012 863 870 10.1200/JCO.2011.35.6345 Epub 2012/01/05 22215748 PubMed Central PMCID: PMC3295572
9. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin. Pharmacol. Ther 69 3 2001 89 95 10.1067/mcp.2001.113989 11240971
10. E. Brambilla, W.D. Travis, T.V. Colby, B. Corrin, and Y. Shimosato The new World Health Organization classification of lung tumours Eur. Respir. J. 18 6 2001 1059 1068 11829087
11. W. Brugger, N. Triller, M. Blasinska-Morawiec, S. Curescu, R. Sakalauskas, G.M. Manikhas, and et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer J. Clin. Oncol 29 31 2011 4113 4120 10.1200/JCO.2010.31.8162 Epub 2011/10/05 21969500
12. D.R. Camidge, Y.J. Bang, E.L. Kwak, A.J. Iafrate, M. Varella-Garcia, S.B. Fox, and et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 10 2012 1011 1019 10.1016/S1470-2045(12)70344-3 22954507 PubMed Central PMCID: PMC3936578
13. D.R. Camidge, W. Pao, and L.V. Sequist Acquired resistance to TKIs in solid tumours: learning from lung cancer Nat. Rev. Clin. Oncol 11 8 2014 473 481 10.1038/nrclinonc.2014.104 24981256
14. S. Cardarella, T.M. Ortiz, V.A. Joshi, M. Butaney, D.M. Jackman, D.J. Kwiatkowski, and et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer J. Thorac. Oncol 7 12 2012 1767 1774 10.1097/JTO.0b013e3182745bcb Epub 2012/11/17 23154547 PubMed Central PMCID: PMC3500523
15. Chen Y.F., M.S. Hsieh, Wu S.G., Chang Y.L., J.Y. Shih, Liu Y.N., and et al. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations J. Thorac. Oncol 9 8 2014 1171 1179 10.1097/JTO.0000000000000232 25157770
16. Y.L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, and et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med 363 18 2010 1734 1739 10.1056/NEJMoa1007478 20979473
17. Y.L. Choi, M.E. Lira, Hong M., R.N. Kim, S.J. Choi, Song J.Y., and et al. A novel fusion of TPR and ALK in lung adenocarcinoma J. Thorac. Oncol 9 4 2014 563 566 10.1097/JTO.0000000000000093 24736082
18. J.G. Christensen, Zou H.Y., M.E. Arango, Li Q., J.H. Lee, S.R. McDonnell, and et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther 6 12 Pt 1 2007 3314 3322 10.1158/1535-7163.MCT-07-0365 18089725
19. G.M. Clark Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib Mol. Oncol 1 4 2008 406 412 10.1016/j.molonc.2007.12.001 19383314
20. D.B. Costa, S.T. Schumer, D.G. Tenen, and S. Kobayashi Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations J. Clin. Oncol 26 7 2008 1182 1184 10.1200/JCO.2007.14.9039 author reply 4-6; Epub 2008/03/04 18309959
21. A.S. Crystal, and A.T. Shaw Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer? Clin. Cancer Res 18 17 2012 4479 4481 10.1158/1078-0432.CCR-12-1952 22912388
22. A.S. Crystal, A.T. Shaw, L.V. Sequist, L. Friboulet, M.J. Niederst, E.L. Lockerman, and et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer Science 346 6216 2014 1480 1486 10.1126/science.1254721 25394791
23. M.A. Davare, A. Saborowski, C.A. Eide, C. Tognon, R.L. Smith, J. Elferich, and et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins Proc. Natl. Acad. Sci. U.S.A. 110 48 2013 19519 19524 10.1073/pnas.1319583110 24218589 PubMed Central PMCID: PMC3845150
24. K.D. Davies, and R.C. Doebele Molecular pathways: ROS1 fusion proteins in cancer Clin. Cancer Res 19 15 2013 4040 4045 10.1158/1078-0432.CCR-12-2851 23719267 PubMed Central PMCID: PMC3732549
25. K.D. Davies, A.T. Le, M.F. Theodoro, M.C. Skokan, D.L. Aisner, E.M. Berge, and et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin. Cancer Res 18 17 2012 4570 4579 10.1158/1078-0432.CCR-12-0550 22919003 PubMed Central PMCID: PMC3703205
26. R.C. Doebele, A.B. Pilling, D.L. Aisner, T.G. Kutateladze, A.T. Le, A.J. Weickhardt, and et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin. Cancer Res 18 5 2012 1472 1482 10.1158/1078-0432.CCR-11-2906 22235099 PubMed Central PMCID: PMC3311875
27. A. Drilon, Wang L., A. Hasanovic, Y. Suehara, D. Lipson, P. Stephens, and et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas Cancer Discov 3 6 2013 630 635 10.1158/2159-8290.CD-13-0035 23533264 PubMed Central PMCID: PMC4160032
28. J.A. Engelman, T. Mukohara, K. Zejnullahu, E. Lifshits, A.M. Borras, C.M. Gale, and et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer J. Clin. Invest 116 10 2006 2695 2706 10.1172/JCI28656 Epub 2006/08/15 16906227 PubMed Central PMCID: PMC1570180
29. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Song Y., C. Hyland, J.O. Park, and et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 5827 2007 1039 1043 10.1126/science.1141478 Epub 2007/04/28 17463250
30. V. Fallet, J. Cadranel, H. Doubre, C. Toper, I. Monnet, T. Chinet, and et al. Prospective screening for ALK: clinical features and outcome according to ALK status Eur. J. Cancer 50 7 2014 1239 1246 10.1016/j.ejca.2014.02.001 24589437
31. Fang D.D., Zhang B., Gu Q., M. Lira, Xu Q., Sun H., and et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib J. Thorac. Oncol 9 3 2014 285 294 10.1097/JTO.0000000000000087 24496003
32. L. Friboulet, Li N., R. Katayama, C.C. Lee, J.F. Gainor, A.S. Crystal, and et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Discov 4 6 2014 662 673 10.1158/2159-8290.CD-13-0846 24675041 PubMed Central PMCID: PMC4068971
33. S.M. Gadgeel, L. Gandhi, G.J. Riely, A.A. Chiappori, H.L. West, M.C. Azada, and et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Lancet Oncol 15 10 2014 1119 1128 10.1016/S1470-2045(14)70362-6 25153538
34. U. Gatzemeier, G. Groth, C. Butts, N. Van Zandwijk, F. Shepherd, A. Ardizzoni, and et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer Ann. Oncol 15 1 2004 19 27 14679114
35. J.R. Grandis, and J.C. Sok Signaling through the epidermal growth factor receptor during the development of malignancy Pharmacol. Ther 102 1 2004 37 46 10.1016/j.pharmthera.2004.01.002 15056497
36. S.L. Graziano, G.P. Gamble, N.B. Newman, L.Z. Abbott, M. Rooney, S. Mookherjee, and et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer J. Clin. Oncol 17 2 1999 668 675 Epub 1999/03/18 10080613
37. J.E. Grilley-Olson, D.N. Hayes, D.T. Moore, K.O. Leslie, M.D. Wilkerson, B.F. Qaqish, and et al. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets Arch. Pathol. Lab. Med 137 1 2013 32 40 10.5858/arpa.2012-0033-OA 22583114
38. J.M. Heuckmann, H. Balke-Want, F. Malchers, M. Peifer, M.L. Sos, M. Koker, and et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants Clin. Cancer Res 18 17 2012 4682 4690 10.1158/1078-0432.CCR-11-3260 22912387
39. F.R. Hirsch, B. Helfrich, W.A. Franklin, M. Varella-Garcia, D.C. Chan, and P.A. Bunn Jr. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines Clin. Breast Cancer 3 Suppl. 1 2002 12 16 12057039
40. F.R. Hirsch, A. Spreafico, S. Novello, M.D. Wood, L. Simms, and M. Papotti The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review J. Thorac. Oncol 3 12 2008 1468 1481 10.1097/JTO.0b013e318189f551 19057275
41. Hong M., R.N. Kim, Song J.Y., S.J. Choi, E. Oh, M.E. Lira, and et al. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma J. Thorac. Oncol 9 3 2014 419 422 10.1097/JTO.0000000000000061 24518094
42. P.A. Janne, and B.E. Johnson Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors Clin. Cancer Res 12 14 Pt 2 2006 4416s 4420s 10.1158/1078-0432.CCR-06-0555 16857820
43. Ju Y.S., W.C. Lee, J.Y. Shin, S. Lee, T. Bleazard, Won J.K., and et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing Genome Res 22 3 2012 436 445 10.1101/gr.133645.111 22194472 PubMed Central PMCID: PMC3290779
44. R. Katayama, T.M. Khan, C. Benes, E. Lifshits, H. Ebi, V.M. Rivera, and et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Proc. Natl. Acad. Sci. U.S.A. 108 18 2011 7535 7540 10.1073/pnas.1019559108 21502504 PubMed Central PMCID: PMC3088626
45. R. Katayama, A.T. Shaw, T.M. Khan, M. Mino-Kenudson, B.J. Solomon, B. Halmos, and et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers Sci. Transl. Med 4 120 2012 120ra17 10.1126/scitranslmed.3003316 22277784 PubMed Central PMCID: PMC3385512
46. R. Katayama, L. Friboulet, S. Koike, E.L. Lockerman, T.M. Khan, J.F. Gainor, and et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib Clin. Cancer Res 20 22 2014 5686 5696 10.1158/1078-0432.CCR-14-1511 25228534 PubMed Central PMCID: PMC4233168
47. P. Keohavong, M.A. DeMichele, A.C. Melacrinos, R.J. Landreneau, R.J. Weyant, and J.M. Siegfried Detection of K-ras mutations in lung carcinomas: relationship to prognosis Clin. Cancer Res 2 2 1996 411 418 9816185
48. H.R. Kim, H.S. Shim, J.H. Chung, Y.J. Lee, Hong Y.K., S.Y. Rha, and et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement Cancer 118 3 2012 729 739 10.1002/cncr.26311 21720997
49. S. Kim, T.M. Kim, D.W. Kim, H. Go, B. Keam, S.H. Lee, and et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer J. Thorac. Oncol 8 4 2013 415 422 10.1097/JTO.0b013e318283dcc0 23344087
50. L.N. Klapper, S. Glathe, N. Vaisman, N.E. Hynes, G.C. Andrews, M. Sela, and et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proc. Natl. Acad. Sci. U.S.A. 96 9 1999 4995 5000 10220407 PubMed Central PMCID: PMC21805
51. T. Kohno, H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, T. Nammo, and et al. KIF5B-RET fusions in lung adenocarcinoma Nat. Med 18 3 2012 375 377 10.1038/nm.2644 22327624
52. J.P. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A.J. Holmes, and et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin. Cancer Res 14 13 2008 4275 4283 10.1158/1078-0432.CCR-08-0168 18594010 PubMed Central PMCID: PMC3025451
53. E.L. Kwak, Y.J. Bang, D.R. Camidge, A.T. Shaw, B. Solomon, R.G. Maki, and et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med 363 18 2010 1693 1703 10.1056/NEJMoa1006448 20979469 PubMed Central PMCID: PMC3014291
54. C.J. Langer, B. Besse, A. Gualberto, E. Brambilla, and J.C. Soria The evolving role of histology in the management of advanced non-small-cell lung cancer J. Clin. Oncol 28 36 2010 5311 5320 10.1200/JCO.2010.28.8126 21079145
55. J.K. Lee, H.S. Park, D.W. Kim, K. Kulig, T.M. Kim, S.H. Lee, and et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer Cancer 118 14 2012 3579 3586 10.1002/cncr.26668 22086654
56. Li S., Qi X., Huang Y., Liu D., Zhou F., and Zhou C. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer Clin. Lung Cancer 16 2 2015 86 91 10.1016/j.cllc.2014.09.011 25458559
57. H. Linardou, I.J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, P. Kosmidis, and et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 10 2008 962 972 10.1016/S1470-2045(08)70206-7 Epub 2008/09/23 18804418
58. D. Lipson, M. Capelletti, R. Yelensky, G. Otto, A. Parker, M. Jarosz, and et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Nat. Med 18 3 2012 382 384 10.1038/nm.2673 22327622 PubMed Central PMCID: PMC3916180
59. Liu L., Shao X., Gao W., Bai J., Wang R., Huang P., and et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data J. Thorac. Oncol 5 12 2010 1922 1932 21155183
60. A. Lopez-Chavez, A. Thomas, A. Rajan, M. Raffeld, B. Morrow, R. Kelly, and et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial J. Clin. Oncol 2015 10.1200/JCO.2014.58.2007 25667274
61. C.M. Lovly, N.T. McDonald, Chen H., S. Ortiz-Cuaran, L.C. Heukamp, Yan Y., and et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer Nat. Med 20 9 2014 1027 1034 10.1038/nm.3667 25173427 PubMed Central PMCID: PMC4159407
62. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med 350 21 2004 2129 2139 10.1056/NEJMoa040938 Epub 2004/05/01 15118073
63. H. Mano Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer Cancer Sci 99 12 2008 2349 2355 10.1111/j.1349-7006.2008.00972.x 19032370
64. Mao C., Qiu L.X., Liao R.Y., Du F.B., Ding H., Yang W.C., and et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer 69 3 2010 272 278 10.1016/j.lungcan.2009.11.020 Epub 2009/12/22 20022659
65. T.H. Marsilje, Pei W., Chen B., Lu W., T. Uno, Jin Y., and et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J. Med. Chem 56 14 2013 5675 5690 10.1021/jm400402q 23742252
66. M.P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, D. Conte, and et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues Am. J. Pathol 174 2 2009 661 670 10.2353/ajpath.2009.080755 19147828 PubMed Central PMCID: PMC2630573
67. D. Matsubara, Y. Kanai, S. Ishikawa, S. Ohara, T. Yoshimoto, T. Sakatani, and et al. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad J. Thorac. Oncol 7 12 2012 1872 1876 10.1097/JTO.0b013e3182721ed1 23154560
68. J. Mazieres, S. Peters, B. Lepage, A.B. Cortot, F. Barlesi, M. Beau-Faller, and et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives J. Clin. Oncol 31 16 2013 1997 2003 10.1200/JCO.2012.45.6095 23610105
69. U. McDermott, A.J. Iafrate, N.S. Gray, T. Shioda, M. Classon, S. Maheswaran, and et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res 68 9 2008 3389 3395 10.1158/0008-5472.CAN-07-6186 18451166
70. S.W. Morris, M.N. Kirstein, M.B. Valentine, K.G. Dittmer, D.N. Shapiro, D.L. Saltman, and et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 263 5151 1994 1281 1284 8122112
71. S. Mukhopadhyay, N.A. Pennell, S.M. Ali, J.S. Ross, Ma P.C., and V. Velcheti RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib J. Thorac. Oncol 9 11 2014 1714 1719 10.1097/JTO.0000000000000323 25436805
72. N. Normanno, A. De Luca, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, and et al. Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 1 2006 2 16 10.1016/j.gene.2005.10.018 16377102
73. K. Ohashi, L.V. Sequist, M.E. Arcila, T. Moran, J. Chmielecki, Lin Y.L., and et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 Proc. Natl. Acad. Sci. U.S.A. 109 31 2012 E2127 E2133 10.1073/pnas.1203530109 Epub 2012/07/10 22773810 PubMed Central PMCID: PMC3411967
74. C.N. Oldenhuis, S.F. Oosting, J.A. Gietema, and E.G. de Vries Prognostic versus predictive value of biomarkers in oncology Eur. J. Cancer 44 7 2008 946 953 10.1016/j.ejca.2008.03.006 18396036
75. Ou S.H., S.J. Klempner, J.R. Greenbowe, M. Azada, A.B. Schrock, S.M. Ali, and et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib J. Thorac. Oncol 9 12 2014 1821 1825 10.1097/JTO.0000000000000368 25393796
76. Ou S.H., J. Greenbowe, Z.U. Khan, M.C. Azada, J.S. Ross, P.J. Stevens, and et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib Lung Cancer 2015 10.1016/j.lungcan.2015.02.005 25736571
77. G.R. Oxnard, P.C. Lo, M. Nishino, S.E. Dahlberg, N.I. Lindeman, M. Butaney, and et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions J. Thorac. Oncol 8 2 2013 179 184 10.1097/JTO.0b013e3182779d18 23328547 PubMed Central PMCID: PMC3549533
78. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, and et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 2004 1497 1500 10.1126/science.1099314 15118125
79. J.H. Paik, C.M. Choi, H. Kim, S.J. Jang, G. Choe, D.K. Kim, and et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma Lung Cancer 76 3 2012 403 409 10.1016/j.lungcan.2011.11.008 22129856
80. Pan Y., Zhang Y., Li Y., Hu H., Wang L., Li H., and et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features Lung Cancer 84 2 2014 121 126 10.1016/j.lungcan.2014.02.007 24629636
81. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, and et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U.S.A. 101 36 2004 13306 13311 10.1073/pnas.0405220101 15329413 PubMed Central PMCID: PMC516528
82. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, and et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 3 2005 e73 10.1371/journal.pmed.0020073 Epub 2005/03/02 15737014 PubMed Central PMCID: PMC549606
83. G.J. Riely, W. Pao, D. Pham, Li A.R., N. Rizvi, E.S. Venkatraman, and et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin. Cancer Res 12 3 Pt 1 2006 839 844 10.1158/1078-0432.CCR-05-1846 16467097
84. K. Rikova, Guo A., Zeng Q., A. Possemato, Yu J., H. Haack, and et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 6 2007 1190 1203 10.1016/j.cell.2007.11.025 18083107
85. V.M. Rimkunas, K.E. Crosby, Li D., Hu Y., M.E. Kelly, Gu T.L., and et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion Clin. Cancer Res 18 16 2012 4449 4457 10.1158/1078-0432.CCR-11-3351 22661537
86. H.J. Ross, G.R. Blumenschein Jr., J. Aisner, N. Damjanov, A. Dowlati, J. Garst, and et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer Clin. Cancer Res 16 6 2010 1938 1949 10.1158/1078-0432.CCR-08-3328 20215545
87. H.H. Rossing, M. Grauslund, E.M. Urbanska, L.C. Melchior, C.K. Rask, J.C. Costa, and et al. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report BMC Res. Notes 6 2013 489 10.1186/1756-0500-6-489 24279718 PubMed Central PMCID: PMC3879082
88. H. Sakamoto, T. Tsukaguchi, S. Hiroshima, T. Kodama, T. Kobayashi, T.A. Fukami, and et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 19 5 2011 679 690 10.1016/j.ccr.2011.04.004 21575866
89. M. Santoro, G. Chiappetta, A. Cerrato, D. Salvatore, Zhang L., G. Manzo, and et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice Oncogene 12 8 1996 1821 1826 8622903
90. T. Sasaki, S.J. Rodig, L.R. Chirieac, and P.A. Janne The biology and treatment of EML4-ALK non-small cell lung cancer Eur. J. Cancer 46 10 2010 1773 1780 10.1016/j.ejca.2010.04.002 20418096 PubMed Central PMCID: PMC2888755
91. T. Sasaki, J. Koivunen, A. Ogino, M. Yanagita, S. Nikiforow, Zheng W., and et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res 71 18 2011 6051 6060 10.1158/0008-5472.CAN-11-1340 21791641 PubMed Central PMCID: PMC3278914
92. G. Scagliotti, T. Brodowicz, F.A. Shepherd, C. Zielinski, J. Vansteenkiste, C. Manegold, and et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J. Thorac. Oncol 6 1 2011 64 70 10.1097/JTO.0b013e3181f7c6d4 21119545
93. G.V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, and et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J. Clin. Oncol 26 21 2008 3543 3551 10.1200/JCO.2007.15.0375 18506025
94. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B. Turke, P. Fidias, and et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci. Transl. Med 3 75 2011 75ra26 10.1126/scitranslmed.3002003 21430269 PubMed Central PMCID: PMC3132801
95. A.T. Shaw, and B. Solomon Targeting anaplastic lymphoma kinase in lung cancer Clin. Cancer Res 17 8 2011 2081 2086 10.1158/1078-0432.CCR-10-1591 21288922
96. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, S.R. Digumarthy, D.B. Costa, R.S. Heist, and et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J. Clin. Oncol 27 26 2009 4247 4253 10.1200/JCO.2009.22.6993 19667264 PubMed Central PMCID: PMC2744268
97. A.T. Shaw, D.W. Kim, K. Nakagawa, T. Seto, L. Crino, M.J. Ahn, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med 368 25 2013 2385 2394 10.1056/NEJMoa1214886 23724913
98. A.T. Shaw, D.W. Kim, R. Mehra, Tan D.S., E. Felip, L.Q. Chow, and et al. Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med 370 13 2014 1189 1197 10.1056/NEJMoa1311107 24670165 PubMed Central PMCID: PMC4079055
99. A.T. Shaw, Ou S.H., Y.J. Bang, D.R. Camidge, B.J. Solomon, R. Salgia, and et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer N. Engl. J. Med 371 21 2014 1963 1971 10.1056/NEJMoa1406766 25264305 PubMed Central PMCID: PMC4264527
100. H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, and et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas Cancer Res 65 5 2005 1642 1646 10.1158/0008-5472.CAN-04-4235 15753357
101. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 1987 177 182 3798106
102. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, and et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 1989 707 712 2470152
103. R.J. Slebos, R.E. Kibbelaar, O. Dalesio, A. Kooistra, J. Stam, C.J. Meijer, and et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N. Engl. J. Med 323 9 1990 561 565 10.1056/NEJM199008303230902 2199829
104. M. Soda, Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, and et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 7153 2007 561 566 10.1038/nature05945 Epub 2007/07/13 17625570
105. B.J. Solomon, T. Mok, D.W. Kim, Wu Y.L., K. Nakagawa, T. Mekhail, and et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer N. Engl. J. Med 371 23 2014 2167 2177 10.1056/NEJMoa1408440 25470694
106. P. Stephens, C. Hunter, G. Bignell, S. Edkins, H. Davies, J. Teague, and et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 7008 2004 525 526 10.1038/431525b 15457249
107. K. Suda, K. Tomizawa, M. Fujii, H. Murakami, H. Osada, Y. Maehara, and et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib J. Thorac. Oncol 6 7 2011 1152 1161 10.1097/JTO.0b013e318216ee52 Epub 2011/05/21 21597390
108. M. Suzuki, H. Makinoshima, S. Matsumoto, A. Suzuki, S. Mimaki, K. Matsushima, and et al. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo Cancer Sci 104 7 2013 896 903 10.1111/cas.12175 23578175
109. K. Takeuchi, Y.L. Choi, M. Soda, K. Inamura, Y. Togashi, S. Hatano, and et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts Clin. Cancer Res 14 20 2008 6618 6624 10.1158/1078-0432.CCR-08-1018 18927303
110. K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata, S. Hatano, and et al. RET, ROS1 and ALK fusions in lung cancer Nat. Med 18 3 2012 378 381 10.1038/nm.2658 22327623
111. K. Takezawa, V. Pirazzoli, M.E. Arcila, C.A. Nebhan, Song X., E. de Stanchina, and et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation Cancer Discov 2 10 2012 922 933 10.1158/2159-8290.CD-12-0108 Epub 2012/09/08 22956644 PubMed Central PMCID: PMC3473100
112. J. Tanizaki, I. Okamoto, T. Okabe, K. Sakai, K. Tanaka, H. Hayashi, and et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer Clin. Cancer Res 18 22 2012 6219 6226 10.1158/1078-0432.CCR-12-0392 22843788
113. Y. Togashi, M. Soda, S. Sakata, E. Sugawara, S. Hatano, R. Asaka, and et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only PLoS ONE 7 2 2012 e31323 10.1371/journal.pone.0031323 22347464 PubMed Central PMCID: PMC3275577
114. G. Toyokawa, and T. Seto Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance Respir. Investig 52 6 2014 330 338 10.1016/j.resinv.2014.06.005 25453376
115. W.D. Travis, E. Brambilla, M. Noguchi, A.G. Nicholson, K.R. Geisinger, Y. Yatabe, and et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma J. Thorac. Oncol 6 2 2011 244 285 10.1097/JTO.0b013e318206a221 21252716
116. L.C. Villaruz, M.A. Socinski, D.E. Cunningham, S.I. Chiosea, T.F. Burns, J.M. Siegfried, and et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma Cancer 119 12 2013 2268 2274 10.1002/cncr.28039 23526491 PubMed Central PMCID: PMC3674175
117. Wang R., Hu H., Pan Y., Li Y., Ye T., Li C., and et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer J. Clin. Oncol 30 35 2012 4352 4359 10.1200/JCO.2012.44.1477 23150706
118. D.W. Wong, E.L. Leung, K.K. So, I.Y. Tam, A.D. Sihoe, Cheng L.C., and et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 115 8 2009 1723 1733 10.1002/cncr.24181 19170230
119. Wu J.Y., Wu S.G., Yang C.H., C.H. Gow, Chang Y.L., Yu C.J., and et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response Clin. Cancer Res 14 15 2008 4877 4882 10.1158/1078-0432.CCR-07-5123 18676761
120. Wu S.G., Y.W. Kuo, Chang Y.L., J.Y. Shih, Chen Y.H., M.F. Tsai, and et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR J. Thorac. Oncol 7 1 2012 98 104 10.1097/JTO.0b013e3182370e30 22124476
121. Xu W., S. Soga, K. Beebe, M.J. Lee, Y.S. Kim, J. Trepel, and et al. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition Br. J. Cancer 97 6 2007 741 744 10.1038/sj.bjc.6603950 17712310 PubMed Central PMCID: PMC2360392
122. Yang P., K. Kulig, J.M. Boland, M.R. Erickson-Johnson, A.M. Oliveira, J. Wampfler, and et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma J. Thorac. Oncol 7 1 2012 90 97 10.1097/JTO.0b013e31823c5c32 22134072 PubMed Central PMCID: PMC3931519
123. H. Yasuda, S. Kobayashi, and D.B. Costa EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications Lancet Oncol 13 1 2012 e23 e31 10.1016/S1470-2045(11)70129-2 21764376
124. K. Yokota, H. Sasaki, K. Okuda, S. Shimizu, M. Shitara, Y. Hikosaka, and et al. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung Oncol. Rep 28 4 2012 1187 1192 10.3892/or.2012.1908 22797671
125. Yu H.A., M.E. Arcila, N. Rekhtman, Sima C.S., M.F. Zakowski, W. Pao, and et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin. Cancer Res 19 8 2013 2240 2247 10.1158/1078-0432.CCR-12-2246 Epub 2013/03/09 23470965 PubMed Central PMCID: PMC3630270
126. Yu H.A., Sima C.S., Shen R., S. Kass, J. Gainor, A. Shaw, and et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas J. Thorac. Oncol 10 3 2015 431 437 10.1097/JTO.0000000000000432 25415430
127. Zhang N.N., Liu Y.T., Ma L., Wang L., Hao X.Z., Yuan Z., and et al. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy PLoS ONE 9 1 2014 e84501 10.1371/journal.pone.0084501 24404167 PubMed Central PMCID: PMC3880316
128. Zhang X., Zhang S., Yang X., Yang J., Zhou Q., Yin L., and et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Mol. Cancer 9 2010 188 10.1186/1476-4598-9-188 20624322 PubMed Central PMCID: PMC2908583
129. Zhu C.Q., G. da Cunha Santos, Ding K., A. Sakurada, J.C. Cutz, Liu N., and et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J. Clin. Oncol 26 26 2008 4268 4275 10.1200/JCO.2007.14.8924 Epub 2008/07/16. 18626007